Natco Pharma's Mekaguda API unit completes USFDA inspection
NATCO Pharma announced conclusion of US FDA Inspection at its Mekaguda, Hyderabad Active Pharmaceutical Ingredients (API) Unit The U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from 9th June 13th June 2025. On conclusion of the inspection, the Company received 1 (One) observation in the Form-483. The Company believes that the observation is procedural in nature. The Company is confident to address this observation comprehensively.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
a day ago
- Economic Times
A Tale of Yaay! and Hmm: Is India's growth story impressive, or disappointing — or a bit of both?
Purchasing power, stop running away! We're doing fine! India has become the world's 5th-largest economy, eclipsing former economic giants like Britain. In a matter of 1-2 years, it should be the 4th-largest, surpassing Japan. Post-pandemic economic growth is nothing to be scoffed at. India is the world's fastest-growing major economy. Over the past 3 years, a rather turbulent period for the world economy, India's GDP increased at nearly 8% definitely. Yet, is the rising euphoria on India's escalating economic ranking justified? Perhaps. But only after we acknowledge the statistical meaning of being among the world's top-ranked economies. India is the world most populous country. In per-capita terms, we are still ranked as low middle-income. In per-capita nominal GDP, India is 143rd in a ranking of 194 countries. Adjusting for purchasing power parity (PPP), it's at 125th - the rank going up a few notches, but not very much. Humbling, yes. But let's not minimise the importance of being among the top 5 economies in overall GDP. China is 69th in nominal per-capital GDP, and 72nd in PPP per-capita GDP. Yet, its influence on the world stage is not diminished by its per-capita income ranking. China's economic and strategic influence is next to none, other than the US', and sometimes even an example, while most nations have cowed into pleasing Donald Trump and accepted his trade deals, China has decided to fight - and appears to be winning. Many countries are weighing whether they should develop closer alliances with China or the US, and how the others will India's influence will also be measured by its overall ranking in GDP, and not just by its per-capita ranking. Yet, let's keep in view that gap between India and the top two world economies. The US economy is $30 tn in nominal GDP. The Chinese economy is $19 tn. India's is far, far below at $3.9 tn. Humbling, vs expectations: that's the other aspect of India's growth story. In 2018, GoI pledged that India would be a $5 tn economy by 2025. This was a target that many experts viewed with amused scepticism. Of course, progress was halted by the two years of the pandemic. But for those long waiting for the arrival of the $5 tn economy, it's still disappointing to see that we are just halfway towards the 2018-19, India's GDP was $2.8 tn. In 2024-25, it's still $1.1 tn short of the target. Now we hope to achieve that target by of leading sectors - where the world acknowledges India's influence - also brings a mixed tale of optimism and caution. India is the world's largest user of ChatGPT, and, according to a Microsoft, Bain & Company, and Internet and Mobile Association of India (IAMAI) report, home to 16% of the world's AI talent. Impressive, has the ambition to lead the world in AI and Narendra Modi says, 'AI will remain incomplete without India.' Yet, so far, India doesn't have an indigenous foundational language model, and it's 3-5 years away from developing domestic AI chips. It lags substantially behind other nations in attracting investment in by Stanford University researchers suggest that India received only $1.2 bn in private investment in AI. Of course, the US received the lion's share - $109 bn. But China received 7x than India. A recent article in The Economist asks whether India can be an AI winner. It cautiously concludes that it has a lot to do to lead the most-talked-about achievement on the manufacturing front is that Apple is now assembling 20% of its smartphones sold worldwide in India. By 2026, it is planning to assemble in India all smartphones it will sell in the US. Again, impressive. Yet, the humbling reality is that India is simply assembling the phones, with almost all of their parts being manufactured in China or Southeast Asia. Hopefully, this will change once Foxconn, Apple's top supplier, sets up production facilities in biggest propeller for future economic growth is investment in Rundefined the US 3.5% of its even-larger in sectors where India has emerged as a top global supplier, investment in R&D is pathetic. India often labels itself the 'pharmacy of the world'. Indian pharma supplies 20% of all generic drugs globally, and 40% of generic drugs used in the US. Generic drugs do not need R& the non-generic sector is substantially driven by R&D. According to the Journal of Medicinal Chemistry, in pharmaceuticals, China's R&D investment is 16x India's. India imports 70% of its drug ingredients from China. Clearly, in some sense, we are far behind China even in sectors where we have a major global presence. (Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. How Vedanta's Anil Agarwal bettered Warren Buffett in returns Rivers are moving more goods than before. But why aren't they making a splash yet? Why Infy's Parekh takes home more than TCS' CEO despite being smaller Is India ready to hit the aspirational 8% growth mark? Aadit Palicha on Zepto dark store raid, dark patterns, and IPO Stock Radar: MCX rallies over 50% in just 3 months to hit fresh highs! What should investors do in June – buy or book profits? Metal stocks: Candidates for tactical and contrarian investing? 6 metal stocks with an upside potential of up to 39% Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports Plus
India.com
a day ago
- India.com
Meet woman, daughter of India's richest pharma tycoon, she now leads Rs 3950000000000 company, she is…, her business is…
Vidhi Shanghvi, Sun Pharma Vidhi Shanghvi is daughter of Dilip Shanghvi, a famous Pharma businessman. She is in headlines for her role in Sun Pharma, one of India's biggest pharmaceutical companies. His net worth is around $25 billion and known as India's richest pharma billionaire. He is also among the top 100 richest people in the world. But now, his daughter Vidhi Shanghvi has also started handling his business. Who Is Vidhi Shanghvi? Vidhi Shanghvi is an Executive Director in Sun Pharma. After 13 years of experience, she now leads Sun Pharma's Consumer Healthcare and India Distribution. Sun Pharma was founded by her father, Dilip Shanghvi in 1983. They started making psychiatric drugs and slowly became India's most valuable pharma company, with a market capitalisation of Rs 3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term. Vidhi Shanghvi Educational Background Vidhi graduated from the Wharton School at the University of Pennsylvania. In Sun Pharma, she used her education in marketing and consumer healthcare. She began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She also handled many marketing campaigns. After the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi became the Business Head of the company's Consumer Healthcare Division. She has played a big role in the growth of the products like Revital H and Volini in retail stores, pharmacies, and online platforms in India. She also has expertise in various fields like marketing, brand building, project and alliance management, and distribution. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform gives free, holistic mental health solutions to individuals for their mental well-being.
Business Standard
2 days ago
- Business Standard
Suzlon Energy allots Equity Shares
Under ESOPSuzlon Energy has approved allotment of 36,44,500 fully paid-up equity shares of the Company having a face value of Rs.2/- each aggregating to Rs.3,30,95,500/- for cash at a premium in dematerialised form to the option grantees, pursuant to the exercise of the options granted to the eligible employees of the Company and its subsidiaries under ESOP by Capital Market - Live News
